FISIOLOGÍA Y FARMACOLOGÍA
Fachbereich
JAVIER
VAQUERO RODRÍGUEZ
Investigador
Publikationen, an denen er mitarbeitet JAVIER VAQUERO RODRÍGUEZ (23)
2024
-
Experimental Model of Biliary Tract Cancers: Subcutaneous Xenograft of Human Cell Lines in Immunodeficient Nude Mice
Methods in molecular biology (Clifton, N.J.), Vol. 2769, pp. 87-98
2023
-
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480
-
Intrinsic cancer cell phosphoinositide 3-kinase δ regulates fibrosis and vascular development in cholangiocarcinoma
Liver International, Vol. 43, Núm. 12, pp. 2776-2793
-
TGFβ-induced circLTBP2 predicts a poor prognosis in intrahepatic cholangiocarcinoma and mediates gemcitabine resistance by sponging miR-338-3p
JHEP Reports, Vol. 5, Núm. 12
2022
-
Genetic alterations shaping tumor response to anti-EGFR therapies
Drug Resistance Updates, Vol. 64
-
Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)
Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734
2021
-
Cholangiopathy aggravation is caused by VDR ablation and alleviated by VDR-independent vitamin D signaling in ABCB4 knockout mice
Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1867, Núm. 4
-
The tgf-β pathway: A pharmacological target in hepatocellular carcinoma?
Cancers, Vol. 13, Núm. 13
-
Zinc Finger E-Box Binding Homeobox 1 Promotes Cholangiocarcinoma Progression Through Tumor Dedifferentiation and Tumor–Stroma Paracrine Signaling
Hepatology, Vol. 74, Núm. 6, pp. 3194-3212
2020
2019
-
Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance
Liver International, Vol. 39, Núm. S1, pp. 43-62
2018
-
MicroRNA-506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation
Hepatology, Vol. 67, Núm. 4, pp. 1420-1440
2016
-
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
Nature Reviews Gastroenterology and Hepatology, Vol. 13, Núm. 5, pp. 261-280
2015
-
E-cadherin, guardian of liver physiology
Clinics and Research in Hepatology and Gastroenterology, Vol. 39, Núm. 1, pp. 3-6
2013
-
Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds
Biochimica et Biophysica Acta - Molecular Cell Research, Vol. 1833, Núm. 10, pp. 2212-2219
-
Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition
Biochemical Pharmacology, Vol. 86, Núm. 7, pp. 926-939
-
Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib
Hepatology, Vol. 58, Núm. 3, pp. 1065-1073
-
FXR-dependent and -independent interaction of glucocorticoids with the regulatory pathways involved in the control of bile acid handling by the liver
Biochemical Pharmacology, Vol. 85, Núm. 6, pp. 829-838
-
Papel del receptor nuclear de ácidos biliares NR1H4 (“farnesoid X receptor”, FXR) en el control de la expresión de genes implicados en el desarrollo de quimiorresistencia. Características funcionales de sus isoformas
Papel del receptor nuclear de ácidos biliares NR1H4 (“farnesoid X receptor”, FXR) en el control de la expresión de genes implicados en el desarrollo de quimiorresistencia. Características funcionales de sus isoformas
2012
-
Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta
Molecular Pharmacology, Vol. 81, Núm. 2, pp. 273-283